Divergent Immunomodulation Capacity of Individual Myelin Peptides-Components of Liposomal Therapeutic against Multiple Sclerosis.

about

Divergent Immunomodulation Capacity of Individual Myelin Peptides-Components of Liposomal Therapeutic against Multiple Sclerosis.

Item

http://www.wikidata.org/entity/Q43293662

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Divergent Immunomodulation Cap ...... ic against Multiple Sclerosis.

@en

Divergent Immunomodulation Cap ...... ic against Multiple Sclerosis.

@nl

type

Item

label

Divergent Immunomodulation Cap ...... ic against Multiple Sclerosis.

@en

Divergent Immunomodulation Cap ...... ic against Multiple Sclerosis.

@nl

prefLabel

Divergent Immunomodulation Cap ...... ic against Multiple Sclerosis.

@en

Divergent Immunomodulation Cap ...... ic against Multiple Sclerosis.

@nl

P1476

Divergent Immunomodulation Cap ...... tic against Multiple Sclerosis

@en

P2093

Alexander Gabibov

http://www.w3.org/2001/XMLSchema#string

Alexey Belogurov

http://www.w3.org/2001/XMLSchema#string

André M Ferreira

http://www.w3.org/2001/XMLSchema#string

Damir I Sakhapov

http://www.w3.org/2001/XMLSchema#string

Ekaterina E Garanina

http://www.w3.org/2001/XMLSchema#string

Ekaterina V Martynova

http://www.w3.org/2001/XMLSchema#string

Farit A Khabirov

http://www.w3.org/2001/XMLSchema#string

Marina O Gomzikova

http://www.w3.org/2001/XMLSchema#string

Timur I Khaibullin

http://www.w3.org/2001/XMLSchema#string

Vilena V Ivanova

http://www.w3.org/2001/XMLSchema#string

P2860

Plasmacytoid dendritic cells: linking innate and adaptive immunity

Multiple sclerosis-a quiet revolution

Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis.

Suppression of ongoing experimental allergic encephalomyelitis in DA rats by novel peptide drug, structural part of human myelin basic protein 46-62.

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ

Immunophenotyping of lymphocyte, monocyte and dendritic cell subsets in normal rhesus macaques by 12-color flow cytometry: clarification on DC heterogeneity

P304

1335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2017.01335

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Albert Rizvanov

Svetlana F. Khaiboullina

E V Granatov

P577

2017-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29085375

http://www.w3.org/2001/XMLSchema#string

P932

5650689

http://www.w3.org/2001/XMLSchema#string